Evidence map›Paper›PMID 36749914›Full record

Trial reportOcular immunology and inflammation2024

Association between Quality of Life and Visual Acuity in a Randomized Clinical Trial of Patients with Uveitis Taking Antimetabolites.

Aheli Chattopadhyay, S R Rathinam, John A Gonzales, Nicole K Kelly, Radhika Thundikandy, Anuradha Kanakath, S Bala Murugan, R Vedhanayaki, Lyndell L Lim, Eric B Suhler and 6 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ocular immunology and inflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01829295 (First-line Antimetabolites as Steroid-sparing Treatment), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01829295 phase3completednot on this map

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2018Enrolled216ConditionsUveitisArmsMycophenolate mofetil, Methotrexate, Prednisone
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 4 countries.

Aheli ChattopadhyayF.I. Proctor Foundation, University of California, San Francisco, California, USA.
S R RathinamUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
John A GonzalesF.I. Proctor Foundation, University of California, San Francisco, California, USA.ORCID 0000-0003-0558-9793
Nicole K KellyF.I. Proctor Foundation, University of California, San Francisco, California, USA.ORCID 0000-0003-1061-2767
Radhika ThundikandyUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
Anuradha KanakathUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Coimbatore, India.
S Bala MuruganUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Pondicherry, India.
R VedhanayakiUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
Lyndell L LimCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Eric B SuhlerCasey Eye Institute, Oregon Health and Science University, OHSU-PSU School of Public Health, and Portland Veterans' Affairs Health Care System, Portland, Oregon, USA.
Hassan A Al-DhibiDivision of Vitreoretinal Surgery and Uveitis, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia.
Thuy DoanF.I. Proctor Foundation, University of California, San Francisco, California, USA.ORCID 0000-0003-2733-8370
Caleb D EbertF.I. Proctor Foundation, University of California, San Francisco, California, USA.
Travis C PorcoF.I. Proctor Foundation, University of California, San Francisco, California, USA.
Nisha R AcharyaF.I. Proctor Foundation, University of California, San Francisco, California, USA.
FAST Research Group
University of California, San Francisco · USAravind Eye Hospital · INCentre for Eye Research Australia · AUKing Khaled Eye Specialist Hospital · SAOregon Health & Science University · US

Funding

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis TrialU10EY021125 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ACHARYA, NISHA · 2012 to 2016
$4.6M
NEI NIH HHS U10 EY021125
6 · The paper itself

Abstract

purposeTo evaluate how changes in visual acuity are associated with changes in quality of life (QoL) among patients with non-infectious uveitis taking antimetabolites.

methodsThis secondary analysis of the multicenter First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial involves 216 participants randomized to methotrexate or mycophenolate mofetil. Vision-related (NEI-VFQ and IND-VFQ) and health-related (PCS and MCS SF-36v2) QoL and visual acuity were measured at baseline and 6-month primary endpoint.

resultsVisual acuity was significantly associated and correlated with all QoL measures (Spearman correlation coefficients = 0.5, 0.5, 0.3, and 0.4 for NEI-VFQ, IND-VFQ, SF-36v2 MCS and PCS, respectively). All observed changes in QoL met or exceeded the minimal clinically important difference definition on each scale. Treatment group was not significantly associated with any QoL measure.

conclusionBy adding insight beyond visual acuity, QoL provides a more comprehensive picture of the patient experience during uveitis treatment.

Indexed as

Quality of LifeUveitisAntimetabolitesHealth StatusHumansSickness Impact ProfileSurveys and QuestionnairesVisual AcuityAntimetabolitesFirst-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trialhealth related quality of lifequality of lifevision related quality of lifevisual acuity

Identifiers

PMID36749914
PMCPMC10404633
OpenAlexW4319461097

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.